Login to Your Account



Fibrocell’s Laviv: The Other Autologous Cell Therapy Story

By Jennifer Boggs
Managing Editor

Wednesday, October 2, 2013
us_resized.jpg

Mention autologous cell therapy and Dendreon Corp.’s commercially challenged prostate cancer vaccine Provenge (sipuleucel-T) usually comes first to mind. Despite an innovative scientific approach – using a patient’s own cells in a personalized treatment – the product’s sales have been hampered by manufacturing complexity, reimbursement issues and increasing competition in the prostate cancer space, so much so that even the much-awaited European approval provoked little excitement. (See BioWorld Today, Sept. 18, 2013.)

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription